Press Releases Antengene Corporation Limited

Equities

6996

KYG039571008

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 am EDT			5-day change	1st Jan Change
0.97 ^HKD	-.--%		-1.02%	-51.50%

May. 02	Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop	MT
Apr. 29	Antengene Corporation Limited Announces That Dr. Kan Chen Will Not Offer Himself for Re-Election At the Annual General Meeting	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Antengene Announces One Oral and Three Poster Presentations at ASCO 2024	Apr. 26	AQ
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress across First-in-Class, Best-in-Class Pipeline	Mar. 25	AQ
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms	Mar. 07	AQ
Antengene Announces Inclusion of XPOVIO in 2023 China's National Reimbursement Drug List	Dec. 15	AQ
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List	Dec. 13	PR
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	Dec. 11	AQ
Antengene Announces XPOVIO Regulatory Approval in Macau for the Treatment of Relapsed and or Refractory Multiple Myeloma	Dec. 07	AQ
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma	Dec. 06	PR
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	Nov. 20	AQ
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	Nov. 16	PR
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs	Nov. 07	PR
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting	Oct. 31	PR
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting	23-09-27	PR
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031	23-09-22	AQ
Antengene Voluntarily Lowers the Price of XPOVIO in China to Allow More Patients with Multiple Myeloma to Benefit from the Drug	23-08-30	AQ
Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline	23-08-28	AQ
Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline	23-08-25	PR
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China	23-08-10	PR
Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States	23-07-17	PR
Antengene Announces XPOVIO Regulatory Approval in Hong Kong for the Treatment of Relapsed and or Refractory Multiple Myeloma	23-07-17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Antengene Corporation Limited

Equities

6996

KYG039571008

Press Releases

Filters